Trial Information

Summary: Nocturnal GERD

Phase 3, double-blind, placebo-controlled study to evaluate the efficacy of the study drug compared to placebo. The study consists of 4 weeks and 21 day screening period with 3 office visits. You will be compensated for your time and travel upon completion of study.

Patient Inclusion Criteria:

• Male or female age 18-65
• History of nocturnal heartburn/GERD associated with sleep disturbance (at least 3 out of 7 nights)
• History of EE diagnosed more than 6 months ago that was responsive to therapy

Patient Exclusion Criteria:

• Allergy to any PPI or Gelusil
• Endoscopic finding of EE during screening endoscopy
• Active gastric ulcer within 30 days of screening
• History of GI Bleed within 6 months of screening
• History of esophageal abnormality (Barrett's esophagus, stricture/narrowing ect.)
• Any other conditions that may cause problems sleeping (sleep apnea,seizure disorder, RLS, insomnia, narcolepsy etc.)
• History of Cancer within previous 5 years (except BCC)
• Shift workers

If you would like to learn more about participating in this study, please send an e-mail message using the form below.